Development of a multi-RNA signature in blood towards a rapid diagnostic test to robustly distinguish patients with acute myocardial infarction

Ended Project Grant Awarded Last action

Award ID
R43HL167483
Recipient
Awarding agency
Obligated
$299,762

Award facts

Assistance listing
93.837 Cardiovascular Diseases Research
Completion date
Place of performance
California, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Chest pain, the main symptom of acute myocardial infarction (AMI), accounts for ~5% of all emergency department (ED) visits. In the absence of ECG abnormalities, diagnostic gold standard for AMI relies on serial troponin (CTN) measurements which are inconclusive in 20-40% of patients, requiring additional testing and prolonged observation in the ED. A missed diagnosis of AMI without proper treatment is life threatening and thus rule-out diagnosis requires very high sensitivity. Hence, a rapid point of care (POC) test utilized as an adjunct to CTN with enhanced diagnostic performance would be revolutionary for risk stratification and timely and safe triaging of patients with suspected MI in ED. Inflammatix is a molecular diagnostics company focused on developing and bringing to market best in class, immune response based, data-driven testing. We developed a point-of-care instrument, myrna™, capable of quantitating up to 64 mrnas in under 30 minutes (with

Transactions

Action Obligated Date
Amendment $0
Original award $299,762

Quick answers

Who received award R43HL167483?

R43HL167483 was awarded to Inflammatix, Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on July 1, 2023.

How much is award R43HL167483 worth?

$299,762 has been obligated on R43HL167483.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login